These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 15934910)

  • 41. Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy.
    Abdollahi A; Folkman J
    Drug Resist Updat; 2010; 13(1-2):16-28. PubMed ID: 20061178
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Recent advances in tumor vasculature targeting using liposomal drug delivery systems.
    Abu Lila AS; Ishida T; Kiwada H
    Expert Opin Drug Deliv; 2009 Dec; 6(12):1297-309. PubMed ID: 19780711
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lysyl oxidase-like-2 promotes tumour angiogenesis and is a potential therapeutic target in angiogenic tumours.
    Zaffryar-Eilot S; Marshall D; Voloshin T; Bar-Zion A; Spangler R; Kessler O; Ghermazien H; Brekhman V; Suss-Toby E; Adam D; Shaked Y; Smith V; Neufeld G
    Carcinogenesis; 2013 Oct; 34(10):2370-9. PubMed ID: 23828904
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis.
    Kumar CC
    Curr Drug Targets; 2003 Feb; 4(2):123-31. PubMed ID: 12558065
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The critical role of vascular endothelial growth factor in tumor angiogenesis.
    Amini A; Masoumi Moghaddam S; Morris DL; Pourgholami MH
    Curr Cancer Drug Targets; 2012 Jan; 12(1):23-43. PubMed ID: 22111836
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Targeting tumor stroma and exploiting mature tumor vasculature to improve anti-cancer drug delivery.
    Bouzin C; Feron O
    Drug Resist Updat; 2007 Jun; 10(3):109-20. PubMed ID: 17452119
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Angiogenesis: Managing the Culprits behind Tumorigenesis and Metastasis.
    Yehya AHS; Asif M; Petersen SH; Subramaniam AV; Kono K; Majid AMSA; Oon CE
    Medicina (Kaunas); 2018 Mar; 54(1):. PubMed ID: 30344239
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Five years of clinical experience with metronomic chemotherapy: achievements and perspectives.
    Emmenegger U; Kerbel RS
    Onkologie; 2007 Dec; 30(12):606-8. PubMed ID: 18063872
    [No Abstract]   [Full Text] [Related]  

  • 49. Molecular mechanisms and therapeutic development of angiogenesis inhibitors.
    Cao Y
    Adv Cancer Res; 2008; 100():113-31. PubMed ID: 18620094
    [TBL] [Abstract][Full Text] [Related]  

  • 50. NGR-based strategies for targeting delivery of chemotherapeutics to tumor vasculature.
    Zou M; Zhang L; Xie Y; Xu W
    Anticancer Agents Med Chem; 2012 Mar; 12(3):239-46. PubMed ID: 22263803
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeting Metabolism to Counteract Tumor Angiogenesis: A Review of Patent Literature.
    Petrillo S; Tolosano E; Munaron L; Genova T
    Recent Pat Anticancer Drug Discov; 2018; 13(4):422-427. PubMed ID: 29807523
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Angiogenesis: new targets for the development of anticancer chemotherapies.
    Gourley M; Williamson JS
    Curr Pharm Des; 2000 Mar; 6(4):417-39. PubMed ID: 10788590
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Angiogenesis: an organizing principle for drug discovery?
    Folkman J
    Nat Rev Drug Discov; 2007 Apr; 6(4):273-86. PubMed ID: 17396134
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antiangiogenic therapy in brain tumors.
    Lakka SS; Rao JS
    Expert Rev Neurother; 2008 Oct; 8(10):1457-73. PubMed ID: 18928341
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A family of models of angiogenesis and anti-angiogenesis anti-cancer therapy.
    D'Onofrio A; Gandolfi A
    Math Med Biol; 2009 Mar; 26(1):63-95. PubMed ID: 19033598
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Angiogenesis inhibitors in cancer therapy.
    Dredge K; Dalgleish AG; Marriott JB
    Curr Opin Investig Drugs; 2003 Jun; 4(6):667-74. PubMed ID: 12901224
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Heterogeneity of tumor endothelial cells and drug delivery.
    Hida K; Maishi N; Sakurai Y; Hida Y; Harashima H
    Adv Drug Deliv Rev; 2016 Apr; 99(Pt B):140-147. PubMed ID: 26626622
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Therapeutic targets of multiple angiogenic factors for the treatment of cancer and metastasis.
    Cao Y; Liu Q
    Adv Cancer Res; 2007; 97():203-24. PubMed ID: 17419947
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficiency of recombinant human TNF in human cancer therapy.
    Lejeune FJ; Liénard D; Matter M; Rüegg C
    Cancer Immun; 2006 Mar; 6():6. PubMed ID: 16551058
    [TBL] [Abstract][Full Text] [Related]  

  • 60. New approach to modeling of antiangiogenic treatment on the basis of Hahnfeldt et al. model.
    Poleszczuk J; Bodnar M; Foryś U
    Math Biosci Eng; 2011 Apr; 8(2):591-603. PubMed ID: 21631148
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.